Asthma Sprays Primatene Mist, Asthmanefrin Await FDA Decisions
This article was originally published in The Tan Sheet
Executive Summary
Armstrong Pharmaceuticals waits to learn the fate of its recently submitted NDA for reformulated Primatene Mist, and Nephron Pharmaceuticals contests FDA’s September warning that its Asthmanefrin is an unapproved drug.
You may also be interested in...
OTC Emergency Asthma Inhaler NDA Survives, Needs Additional Studies
FDA’s request for additional data on Armstrong’s NDA for Primatene HFA – a breath-triggered, epinephrine inhalation aerosol – shows the agency’s interest in expanding consumers’ choices for OTC emergency asthma inhalers beyond the one currently available, racepinephrine with a battery-powered atomizer.
OTC Emergency Asthma Inhaler NDA Survives, Needs Additional Studies
FDA’s request for additional data on Armstrong’s NDA for Primatene HFA – a breath-triggered, epinephrine inhalation aerosol – shows the agency’s interest in expanding consumers’ choices for OTC emergency asthma inhalers beyond the one currently available, racepinephrine with a battery-powered atomizer.
Antiquated Nebulizers Deliver Uneven Asthma Doses – FDA Reviewers
Hand-held rubber ball nebulizers are “antiquated” and deliver inconsistently measured doses, FDA reviewers say in briefing materials prepared for a Feb. 26 advisory committee meeting to discuss removing the devices from the OTC monograph.